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Abstract: Chemosensitive primary sensory neurones expressing the TRPV1 receptor, a molecular integrator of diverse 
noxious stimuli, play a fundamental role in the sensation of pain. Capsaicin, the archetypical ligand of the TRPV1 recep-
tor, is one of the most painful chemical irritants, and its acute administration onto the skin and mucous membranes elicits 
severe pain. However, repeated or high-dose applications of capsaicin, and/or its administration through specific routes 
dramatically decreases the sensitivity of the innervated tissues to noxious chemical and heat stimuli. This review surveys 
the mechanisms of the antinociceptive, anti-inflammatory and anti-hyperalgesic effects of vanilloid agonists applied topi-
cally, or perineurally, or injected into the subarachnoid space in animal experiments and to put these data into a clinical 
perspective. The great body of available experimental evidence indicates that vanilloid agonists exert their antinociceptive 
actions through TRPV1 receptor-mediated selective neurotoxic/neurodegenerative effects directed against somatic and 
visceral C-fibre nociceptive primary afferent fibres. It is expected that vanilloid agonists will broaden the palette of anal-
gesic drugs which do not cause addiction and tachyphylaxis. 
Keywords: Analgesia, capsaicin, neurogenic inflammation, pain, pain management, primary sensory neurone, spinal cord, 
TRPV1. 
INTRODUCTION 
Systematic studies on the regulation of the function of the 
reticulo-endothelial system by histamine and on the mecha-
nisms of histamine desensitization led Nicholaus (Miklós) 
Jancsó to the recognition of the unique pharmacological 
properties of capsaicin and related pungent compounds. In 
his pioneering investigations, he elegantly demonstrated that 
repeated applications of capsaicin, the pungent ingredient of 
the capsicum species, selectively abolished the chemical pain 
sensitivity of the sensory nerve endings of the skin, mucous 
membranes and viscera [1-3]. The capsaicin-induced desen-
sitization of the chemosensitive nerve terminals produced not 
only an impairment of their afferent functions, causing 
chemoanalgesia and the abolition of protective reflexes, but 
also inhibition of the sensory nerve-mediated inflammatory 
reactions, including local vasodilatation (hyperaemia) and 
increased microvascular permeability (plasma protein ex-
travasation and oedema formation), generally referred to as 
neurogenic inflammation [1,3,4]. The abolition of the protec-
tive reflexes (e.g. in the eye wipe test) clearly indicated the 
development of capsaicin-induced analgesia, which rendered 
the animals unresponsive towards the pain-producing effects 
of capsaicin and other exogenous and endogenous chemical 
irritants. It was concluded that (repeated) topical applications 
of capsaicin cause a long-lasting (but frequently reversible) 
inhibition of both the sensory afferent and the local vascular 
“sensory efferent” functions [4,5] of a population of sensory 
nerves. It was apparent from this early stage of the research, 
however, that the action of capsaicin is highly selective for 
these “capsaicin-sensitive” elements of the peripheral nervous 
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system, since neither the (low-threshold) mechanosensitive 
afferents conveying tactile sensation, nor the autonomic or 
somatomotor efferent nerves were affec ed. These observa-
tions provided the first selective pharmacological tool with 
which to study the contribution of the chemosensitive nerves 
to the afferent and local regulatory efferent functions of the 
sensory fibres [6]. Although the use of capsaicin became a 
powerful procedure for study of the physiological and phar-
macological significance of chemosensitive nerve fibres in 
various biological processes, the identity of the primary sen-
sory neurones affected by the actions of capsaicin remained 
largely unknown. Early electrophysiological studies demon-
strated that the chemosensitive afferents activated by cap-
saicin belong among the unmyelinated C-fibre population of 
peripheral nerves responsive to noxious chemical stimuli, but 
not to innocuous mechanical stimuli [7]. These features of 
the capsaicin-sensitive nerves satisfy the classical criteria of 
nociceptors as originally formulated by Sherrington. How-
ever, apart from their functional traits, the capsaicin-sensitive 
afferents remained anatomically indistinguishable from other 
afferent and autonomic efferent C-fibres present in mixed 
peripheral nerves. Moreover, the somata of these nocicep-
tors, which intermingle with other primary sensory neurones 
that convey different modalities in the spinal and cranial 
sensory ganglia, were also undistinguishable. The observa-
tion that the systemic administration of capsaicin to newborn 
animals (rats or, mice) produces a long-lasting (irreversible) 
elimination of chemosensitive small diameter C-fibre pri-
mary sensory neurones, rendering the animals unresponsive 
to capsaicin and other chemical stimuli, was therefore a sig-
nificant step in the study of the mechanisms of nociception 
and pain [8]. These important observations on the neurotoxic 
effects of capsaicin and related vanilloids [9] were later ex-
tended considerably by studies which demonstrated that cap-
saicin can produce similar, though from certain aspects lim-
ited, neurotoxic and/or neurodegenerative effects within the 
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population of chemosensitive primary sensory neurones de-
pending on the site and dose of application and the type of 
vanilloid compound used. Detection of the morphological 
and neurochemical signs (i.e. the depletion of specific neuro-
chemical markers) of the capsaicin-induced selective neu-
rodegeneration and study of the consequences of this chronic 
chemodenervation provided a useful approach to the identifi-
cation of capsaicin-sensitive structures in both the peripheral 
and the central nervous system, and to the detection of their 
contribution to a large variety of physiological and patho-
physiological processes [10,11]. Importantly, this approach 
led to the identification of specific neuropeptides which me-
diate the neurogenic inflammatory response [12,13] and are 
involved in the transmission of pain. This approach had un-
doubtedly certain limitations, which were later partially 
overcome by identification of the specific capsaicin-binding 
site in the sensory neurones, the vanilloid type 1 transient 
receptor potential receptor (TRPV1) protein [14,15] and the 
generation of TRPV1 knock-out transgenic mice [16,17]. A 
substantial body of evidence is now available, indicating that 
the capsaicin sensitivity of the chemosensitive primary sen-
sory neurones is conferred exclusively by this non-selective, 
“polymodal” ion channel, which is the prototype of “sensory 
TRP” receptors and is the first and best-characterized arche-
typical nociceptor-specific molecular transducer identified in 
the peripheral nervous system [18]. Nevertheless, apart from 
being (and remaining) powerful experimental tools in sen-
sory physiology and pharmacology, capsaicin and the related 
vanilloids (and other TRPV1 agonists) have also a signifi-
cant therapeutic potential, which is probably neither ade-
quately recognized nor effectively exploited at present. 
In this review, we briefly summarize the morphological 
and functional consequences of capsaicin-induced neurode-
generation by comparing the different types/routes of cap-
saicin application. We also survey the current knowledge on 
the cellular mechanisms of vanilloid-induced neurotoxicity, 
and highlight the benefits and possible complications of the 
analgesia elicited by perineural/topical applications of cap-
saicin and related vanilloids. We hope that this information, 
may be of help in the recognition of vanilloid-induced anal-
gesia as a valuable option for the management of painful 
conditions, and will promote translation of this method into 
medical practice. 
Acute and Chronic Effects of High-Dose Capsaicin: Neo-
natal, Adult, Perineural and Intrathecal Administrations 
We first briefly discuss the consequences of the selective 
neurotoxic effects of the administration of capsaicin to new-
born animals, which produces the most profound morpho-
logical and functional changes in, and affects the total popu-
lation of capsaicin-sensitive primary sensory neurones. In 
this section, we focus primarily on the changes produced by 
capsaicin in the cutaneous and deep tissue nociceptors (Fig. 
1). Neurotoxic changes affecting the capsaicin-sensitive vis-
ceral afferents and their possible therapeutic implications 
will be discussed separately. 
Neonatal Capsaicin Treatment 
Systemic (subcutaneous) administration of capsaicin (50 
mg/kg b.w.) to newborn animals (rats, mice and dogs) pro-
duces a long-lasting (irreversible) ablation of small-diameter 
C-fibre primary sensory neurones [8,19-22], rendering the 
animals unresponsive to capsaicin and other exogenous (and 
endogenous) algogenic agents and chemical irritants. Cap-
saicin administration during the most sensitive 1-14-days 
postnatal period gives rise to a selective degeneration of pri-
mary sensory neurones in the spinal and cranial sensory gan-
glia and leads to a selective argyrophilic degeneration of 
spinal and cranial primary afferents through a unique, 
chemically induced primary centrifugal degeneration de-
scribed by Cajal [8,23,24]. It reduces the number of (sen-
sory) C-fibres in both the peripheral nerve trunks and the 
spinal dorsal roots [8,24-26], and the density of sensory 
nerves in both the skin and the viscera. In the central nervous 
system, it affects the central terminals of the primary che-
mosensitive afferents, causing a robust degeneration of pre-
synaptic axons and boutons in the superficial dorsal horn of 
the spinal cord, the marginal and caudalis subnuclei of the 
trigeminal nucleus, the nucleus of the solitari tract and the 
area postrema [23]. More recent publications have confirmed 
the practically complete overlap between these central nerv-
ous regions affected by capsaicin-induced argyrophilic de-
generation and the localization of the TRPV1-expressing 
sensory nerve terminals visualized by immuno-histochemistry 
[27]. Quantitative data indicate that approximately 50% of 
the DRG neurons, 70% of the C-fibre afferents in the cuta-
neous nerves and up to 95% of C-fibre dorsal root fibres in 
the rat are affected and later eliminated after neonatal treat-
ment [8,24,25].  
The development of these degenerative morphological 
changes induced by capsaicin is rapid: ultrastructural 
changes in the dorsal root ganglion neurones can be observed 
after less than 30 minutes, in the peripheral nerves and dorsal 
roots after 4 hours [23] and in the spinal cord dorsal horn 
(Rexed’s lamina I and II) after 6-12 hours [28]. The struc-
tural changes are preceded by biochemical changes, such as 
the intracellular accumulation of Ca2+, as shown in vivo by 
Jancsó et al., and activation of proteolytic enzymes [29,30]. 
Even more surprising is the fact, that the overt signs of de-
generation in the perikarya and the central/peripheral ax-
ons/terminals disappear remarkably quickly: degenerating 
neurones in the DRG and axon terminals in the spinal dorsal 
horn are practically absent 24 hours after the injection of 
capsaicin. The rapid clearance of the cellular/axonal debris 
during about 3 days after the treatment is a consequence of the 
activation, migration and phagocytic activity of resident glial 
cells (microglia) and possibly other phagocytotic cells [28].  
Because of the age-dependent technical limitations, as-
sessment of the sensory function in neonates may be compli-
cated, but it seems that the functional consequences of neo-
natal capsaicin treatment develop rather quickly after cap-
saicin treatment. The sensory deficit includes chemoanalge-
sia towards noxious chemical stimuli exerted by capsaicin 
and related compounds, as expressed by the decrease or 
complete extinction of behavioural responses or protective 
reflexes [8]. It has been demonstrated that the most charac-
teristic functional deficit in TRPV1 knock-out animals is the 
decrease in thermal hyperalgesia elicited by the acute (non-
neurogenic) inflammation. It is expected that thermal hyper-
algesia should also be suppressed in capsaicin-induced 
chemical knock-outs.  
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Neonatal treatment with capsaicin results in practically 
complete abolition of the neurogenic inflammatory response 
[8,13,24]. The elimination of neurogenic plasma extravasa-
tion and vasodilatation elicited by chemical irritants (mustard 
oil, xylene or capsaicin) or antidromic electrical stimulation 
of sensory nerves has been demonstrated in the skin and dif-
ferent visceral organs (trachea, ureter and gut). It should ad-
ditionally be noted that the inflammatory reactions induced 
by vasoactive agents such as histamine, bradykinin and sero-
tonin are also significantly decreased, indicating a sensory 
nerve-mediated amplification of acute inflammatory reac-
tions [24,31-33]. Neurogenic vasodilatation mediated by 
vasoactive peptides released from activated nerve terminals 
is also suppressed in the skin [12] and gastrointestinal tract 
[34]. Some observations suggest that the presumed trophic 
effects of the chemosensitive primary sensory neurones too 
are impaired, which might explain the development of skin 
lesions on the face, disturbed hair growth and corneal lesions 
observed after longer survival [35,36].  
Since the large majority of the chemosensitive primary 
sensory neurones are polymodal i.e. heat nociceptors, it is 
not suprising that the sensitivity towards other physical stim-
uli, such as noxius heat, is also decreased in these animals. 
The sensory threshold for noxious heat is significantly in-
creased as measured by various methods [37-39]. Finally, it 
must be emphasized that these morphological and functional 
changes (in the rat) seem to be irreversible, causing a life-
long reduction in the number of sensory neurones and axons 
and deficits in the sensory afferent and efferent functions of 
primary chemosensitive neurones [10,11,18,40-42]. 
Systemic Capsaicin Treatment of Adult Animals 
The systemic capsaicin treatment of adult rodents is gen-
erally referred to as capsaicin desensitization, for this treat-
ment renders animals insensitive to capsaicin and other irri-
tant chemicals. Functional and pharmacological desensitiza-
tion are distinguished (the former is also known as defunc-
tionalization) [43] to indicate that the treatment results in 
 
Fig. (1). Domains of primary sensory neurons labelled in black and gray denote the occurance of unequivocal morphological signs of 
degeneration or changes in the chemical phenotype, e.g. depletion of peptides from the affected neurones. 
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selective insensitivity to the action of capsaicin only, or in a 
general unresponsiveness of the animal to a variety of irritant 
chemicals. In other terms, pharmacological desensitization 
denotes the desensitization of the TRPV1 receptor, whereas 
defunctionalization results from action on other types of TRPs 
and nociceptive channels/receptors, such as ionotropic puri- 
nergic receptor P2X3, proton channels (ASICs), bradykinin 
receptors, serotonergic receptors, prostaglandin and hista-
mine receptors [44,45]. Defunctionalization may result from 
the sensory neurone blocking effect of capsaicin [4]. 
Although systemic capsaicin treatment of adult animals 
technically is equivalent to neonatal treatment (the dose is 
from 50-100 mg/kg to 300 mg/kg b.w. divided into frac-
tions), the morphological and functional consequences on the 
primary sensory neurones are in general less pronounced. 
Possible explanation for the influence of the age and the de-
velopmental stage on capsaicin susceptibility will be dis-
cussed later. Early attempts to demonstrate morphological 
correlates for the capsaicin-induced functional deficits ob-
served in adult animals revealed only limited ultrastructural 
changes in small dorsal root ganglion neurones [46]. Re-
investigation of the capsaicin-induced morphological 
changes in adult (more than 6 weeks old) rats and guinea 
pigs disclosed that about 17% of the lumbar dorsal root gan-
glion neurones exhibited clear-cut signs of degeneration as 
early as 1 hour after the injection of capsaicin [22,47]. Simi-
larly to what was observed in neonates, the degenerating 
neurones exhibited increased cytoplasmic and nuclear baso-
philia, cytoplasmic vacuolization, shrinkage of the nucleus 
and chromatolysis. In addition, extensive argyrophilic de-
generation of the synaptic boutons was seen in the superficial 
dorsal horn and trigeminal brain stem nuclei. Osmiophilic 
degeneration of a large population of unmyelynated C-fibres 
in the dorsal roots was apparent from electron microscopic 
studies. It was also found, that the systemic capsaicin treat-
ment of adult rats produced depletion of the sensory neuronal 
marker enzyme fluoride-resistant acid phosphatase (FRAP) 
[48]. The reduction of other nociceptive neurone specific 
chemical markers, including substance P (SP), somatostatin 
(SOM) and isolectin B4 of Bandeira (Griffonia) simplicifolia 
(IB4) from the spinal dorsal horn is most probably caused by 
the degeneration of the central terminals of the peptidergic 
and non-peptidergic afferent neurones [49,50]. Reduction of 
the TRPV1 immunoreactivity was also recently observed in 
both the spinal cord and the sensory ganglia [51]. Although 
quantitative morphological data revealed a significant dose-
dependent loss of up to 50 per cent of the unmyelinated C 
fibres in peripheral nerves, this reduction was less than that 
observed after neonatal treatment [47]. It was therefore con-
cluded that systemic capsaicin treatment in adult rats pro-
duces degeneration of only a subpopulation of capsaicin-
sensitive neurones. Peripheral terminals have also been re-
ported to be affected following the systemic administration 
of capsaicin, which might explain the sensory deficits ob-
served after such treatment [52-54]. 
Similarly to the morphological alterations the functional 
changes are less severe in adult animals. Although the noci-
ceptive reflexes elicited by chemical irritants are impaired, 
there is only a moderate decrease in neurogenic plasma pro-
tein extravasation after a longer post-treatment period 
[8,22,55]. 
Localized Treatments with Capsaicin 
Although studies of the nociceptive and inflammatory 
phenomena in animals following systemic capsaicin injec-
tions have yielded important information on the mecha-
nism(s) of pain and inflammation, selective blockade of the 
function of capsaicin-sensitive neurones serving a particular 
skin region or organ may be preferable for study of the func-
tional significance of these particular nociceptive afferent 
nerves in targeted regions of tissues or organs. Systemic in-
jections of capsaicin produce generalized initial excitation, 
which is followed by functional blockade and complete or 
partial degeneration of the whole system of capsaicin-
sensitive primary sensory neurones. Three possible applica-
tion schemes have been developed and utilized for the selec-
tive desensitization or destruction of different domains of the 
capsaicin-sensitive neurone: local applications of capsaicin 
close to the termination sites of the peripheral axon terminals 
of sensory neurones (topical application); the direct applica-
tion of capsaicin onto mixed peripheral nerve trunks 
(peri/epineural, intraneural or subepineural application); and 
the injection of capsaicin directly into the subarachnoid 
space, from where it rapidly reaches the central termination 
sites of the primary afferent axons (intrathecal and intracis-
ternal applications). 
Topical Application 
The morphological and functional consequences of the 
topical application of capsaicin onto the skin, the mucous 
membranes or the luminal surfaces of different organs are 
dependent on a variety of factors, which may influence the 
penetration, distribution, absorption and finally the accessi-
bility of the targeted neural elements (axon terminals) to 
capsaicin. These pharmacokinetic factors include the concen-
tration of the drug, the lipo- or hydrophilic characteristics of 
the solvent and the application regime (single or repeated 
applications) and also the anatomical organization, circula-
tion and barrier functions of the given organ/tissue. Since a 
huge variety of different types of treatments and locations 
have been targeted, we focus here on the most frequent and 
well-characterized applications of significant experimental 
and therapeutic value. 
Epicutaneous capsaicin application is probably the most 
straightforward way to manipulate capsaicin-sensitive nerve 
endings terminating in the skin. The morphological proper-
ties of the tissue offer favourable conditions for the passive 
diffusion of lipophilic capsaicin preparations to reach the 
free nerve endings of the unmyelinated nociceptive axons 
which terminate in the most superficial layer of the epider-
mis. Indeed, capsaicin at a relatively low concentration acti-
vates the capsaicin-sensitive nerve endings in man, produc-
ing acute burning pain and thermal and tactile hyperalgesia. 
The redness/erythema which can also be observed at the site 
of or in the close vicinity of the application (flare response) 
is brought about by the release of vasoactive neuropeptides 
from the activated nerve endings [31,32]. In animal studies, 
the applications of capsaicin or similar chemical irritants 
onto the conjuctiva, which elicits characteristic protective 
reflexes (blepharospasm and eye-wiping), is also frequently 
used to assess the functional integrity of chemosensitive 
primary sensory neurones. Repeated epicutaneous or con-
junctival application of capsaicin at concentrations of >0.1% 
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is known to result in the loss of chemogenic pain sensation, 
and cutaneous/conjunctival sensory neurogenic reactions. It 
is highly probable that at low concentrations capsaicin de-
sensitization evolves at the receptorial level, producing the 
blockade of sensory transduction processes. There is con-
vincing evidence that, at higher concentrations or after re-
peated applications of capsaicin, morphological changes 
occur, such as the (reversible) depletion of the intra-
epidermal free nerve endings [56,57]. After the application 
of capsaicin onto the skin, the loss and recovery of the noci-
ceptive functions correlate with the degeneration and subse-
quent regeneration of intra-epidermal nerve endings [56]. 
Similar or even more robust morphological and functional 
changes are observed when capsaicin is injected subcutane-
ously [58]. It is difficult to define the diffusion limits of cap-
saicin following epicutaneous application, but it is possible 
that in the event of intracutaneous application, capsaicin can 
reach more proximal segments of the sensory axons, and 
give rise to a functional blockade and degenerative changes 
in these proximal axon segments, which might resemble the 
effects of perineural capsaicin treatment [59], as will be dis-
cussed later.  
Some visceral organs also provide appropriate targets for 
therapeutic interventions through the use of capsaicin or 
other vanilloids locally to inhibit the activity of capsaicin-
sensitive nerves. The urinary bladder, which is accessible via 
moderately invasive application techniques, is a preferred 
organ, since the role of capsaicin-sensitive afferent nerves is 
well-established in the mechanisms of bladder inflammation 
and painful functional disturbances of micturition [60-65]. 
There is ample clinical evidence of the beneficial effects of 
intravesical capsaicin or resiniferatoxin in patients with hy-
peractive bladder disorders (overactive bladder, detrusor 
instability/overactivity or neurogenic bladder) or interstitial 
cystitis [65,66]. Intravesical application of capsaicin has 
been shown to decrease the pain elicited by bladder empty-
ing and to enhance the compliance and the capacity of the 
bladder. Although such functional improvements ensue 
shortly after the treatment, there is a tendency to a relapse 
after longer periods of time, which can be prevented by re-
peated applications. This indicates that the functional and 
presumed morphological changes in visceral capsaicin-
sensitive sensory neurones are long-lasting, but reversible. 
Observations on the possible morphological changes are 
contradictory. Immunohistochemical studies indicated a re-
duction in the TRPV1-positive and the peptidergic nerve 
fibres in the epithelium and subepithelial layers of the blad-
der mucosa after topical capsaicin or resiniferatoxin treat-
ment [67-70]. An ultrastructural study aimed at detection of 
vanilloid-induced morphological changes in the bladder sen-
sory nerve endings failed to reveal any sign of axonal degen-
eration or damage after the intraluminal application of res-
iniferatoxin [69]. Other in vitro observations, however, indi-
cated that, even at very low (submicromolar) concentrations 
capsaicin may induce severe osmiophilic degeneration of 
unmyelinated afferent axons in the guinea pig ureter [71].  
Administration of Capsaicin into the Subarachnoid 
Space: Intrathecal and Intracisternal Injections 
Injections of capsaicin into the subarachnoid space, either 
intrathecally [72-74] or intracisternally [75,76], have been 
utilized to activate and/or desenzitize the central terminals of 
capsaicin-sensitive primary sensory neurones. The rationale 
of this approach is that capsaicin injected into the cerebro-
spinal fluid can easily cross the liquor-brain barrier and reach 
the terminal segments and the terminals of primary afferent 
axons without affecting the soma and the peripheral axons of 
the C-fibre sensory ganglion neurones. The intracisternal 
injection of capsaicin produces a prompt, but transient vaso-
dilatation in the ear and protective eye and ear-wiping 
movements. These integrated nociceptive responses and the 
peripheral vasodilatation clearly indicate activation of the 
central spinal and trigeminal nociceptive terminals and the 
antidromic propagation of action potentials along the axons 
excited [75,76]. Signs of regional tactile allodynia confined 
to the cutaneous innervation areas of the trigeminal and up-
per cervical nerves are also observed, probably due to a cap-
saicin-induced central sensitization elicited by the transmit-
ters released from the activated capsaicin-sensitive nerve 
endings [75,77]. These changes are later followed by the 
rapid (within minutes) development of selective regional 
chemo- and thermal analgesia, which is attributed to the im-
paired central transmission of the noxious impulses. The 
structural correlate of the analgesia produced by intracister-
nal and intrathecal injections of capsaicin is degeneration of 
the central terminals of the capsaicin-sensitive primary sen-
sory neurones, as demonstrated by light- and electron mi-
croscopy [72,74-76]. Similarly to the effects of the high-dose 
systemic administration of capsaicin, intense argyrophilic 
degeneration is observed in the brainstem trigeminal caudal 
nucleus, the nucleus of the solitari tract and the superficial 
layers of the dorsal horn of the upper segments of the cervi-
cal spinal cord a few hours after the application of capsaicin 
[75,76]. At the electron microscopic level, selective degen-
eration of the glomerular C-type terminals is seen in these 
brainstem areas [76]. The degeneration of the central terminals 
may explain the observations on the depletion of substance 
P, SOM, calcitonin gene-related peptide (CGRP), TRPV1 
immunoreactivity and FRAP or thiamine monophosphatase 
(TMP) activity after intracisternal or intrathecal capsaicin 
and resiniferatoxin applications [72,73,75,76,78,79]. On spi-
nal application at the level of the lumbar segments, apparent 
losses of nociceptor-specific neuronal markers occur from 
the superficial laminae of the spinal cord in the lumbar spinal 
segments, but not in the cervical and upper thoracic seg-
ments [72]. 
The trigeminal ganglion reveals neither morphological 
signs of neuronal degeneration nor depletion of the nocicep-
tor-specific chemical markers observed after intracisternal 
application [76]. Furthermore, chemosensitive ganglion cells 
deprived of their central axons and connections to the central 
nervous system maintain their neurochemical phenotype and 
local regulatory functions [75-77]. In animals treated in-
tracisternally with capsaicin, activation of the peripheral 
chemosensitive nerve endings in the chemodenervated skin 
region produced an apparently intact neurogenic inflamma-
tory response. These experiments clearly showed a dissocia-
tion between the sensory afferent and local regulatory “effer-
ent” functions of the capsaicin-sensitive primary afferent 
neurones and provided evidence that the local regulatory 
functions of these neurones are independent of their central 
connections [76]. This unique situation may also be of sig-
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nificance as regards vanilloid-based therapeutic interven-
tions, since concerns relating to possible impairments of the 
sensory efferent/trophic functions of chemosensitive nerves 
following selective chemical ablation of the capsaicin-
sensitive primary sensory neurones could be prevented [79-
81].  
Perineural Capsaicin Treatment 
The perineural application of capsaicin is a special form 
of topical capsaicin treatment, since the peripheral nerves 
supplying a well-defined part of the skin or deep tissues are 
targeted in this situation. Capsaicin was originally applied in 
a gelfoam cuff, from which the drug reaches the nerve fibres 
within the nerve trunk by diffusion across the epineurinum 
[21,82,83]. There have also been reports on close neural in-
jections [84-86], subperineural or even intraneural injections 
of capsaicin with similar effectiveness. As confirmed by 
many authors, the perineural application of capsaicin at 32 
mM (1%) produces a highly selective and-long lasting (prac-
tically irreversible) functional blockade of the C-fiber affer-
ents running in the affected nerve [87-91]. The acute mor-
phological changes seen shortly after treatment are less char-
acteristic: swollen C-fibres and the subsequent accumulation 
of cell organelles [21,92]. However, a fundamental change is 
observed in the relation between the C-fibres and the glial 
(Schwann) cells 2-3 weeks after the treatment: C-fibres, 
normally embedded in the cytoplasm of the Schwann cell 
processes, lose their tight contact with the glial cells and 
become unwrapped and closely packed together with other 
bare C-fibre axons [93]. Perineural capsaicin treatment does 
not produce an immediate degeneration of peripheral che-
mosensitive axons. Quantitative data have revealed a signifi-
cant, but delayed reduction in the C-fibre count 2-3 months 
after treatment indicating a permanent loss of at least a sub-
population of C-fibre afferent neurones [21,82,89]. This pe-
culiar slow, “dying back” type neuronal degeneration may 
result from a selective blockade of intraneuronal transport 
processes in chemosensitive primary afferent neurons, as 
will be discussed later [94]. Perineural capsaicin treatment 
exerts profound and selective effects on the neurochemical 
phenotype of chemosensitive primary sensory neurones. A 
few days after the treatment, severe downregulation and the 
depletion of several neurochemical markers are observed as 
regards both nociceptive dorsal root ganglion neurones and 
the somatotopically corresponding regions of the spinal dor-
sal horn. The levels of sensory neuropeptides, e.g. SP and 
CGRP and FRAP/TMP activity and IB4 binding are reduced 
after perineural treatment with capsaicin [21,51,95]. At the 
same time, a few markers display an increased expression: 
the transcription factor ATF3, a general marker of neuronal 
distress exhibits a highly selective upregulation in the small 
TRPV1-positive neurones, but not in the large TRPV1-
negative neurones a few days after capsaicin treatment (un-
published observation). This confirms the selectivity of cap-
saicin-induced axonal/neuronal degeneration. The membrane 
ganglioside GM1, the specific binding site for the “b” 
subunit of the cholera holotoxin, is overexpressed in the C-
fibre nociceptive afferents, as demonstrated by the increased 
transganglionic transport of the CTb-HRP conjugate in the 
DRG ganglia and the superficial layers of the spinal dorsal 
horn following perineural capsaicin or RTX treatment 
[96,97]. Earlier observations indicated a rapid decrease in the 
sensitivity of DRG neurones and central terminals towards 
the neurotoxic effects of systemic capsaicin treatment [83]. 
This reduction in capsaicin sensitivity, which is also ob-
served following transection of the peripheral nerves [98,99], 
is explained in part by the reduction of the capsaicin receptor 
protein. After cloning of the TRPV1 receptor, this presump-
tion was confirmed by the strong decreases in both the 
mRNA and TRPV1 protein expression of small and medium 
sized dorsal root ganglion neurones and the TRPV1 im-
munoreactivity in the superficial layers of the spinal dorsal 
horn as early as 4 days after perineural capsaicin treatment 
[51]. Furthermore, use of a mustard oil-induced vascular 
labelling technique to identifiy the cutaneous regions inner-
vated by the saphenous and the sciatic nerves, revealed al-
most complete elimination of the intra-epidermal nerve fi-
bres in the skin regions innervated by the treated sciatic or 
saphenous nerves [59]. It is noteworthy that the morphology 
and density of the palisade-shaped hair follicle afferents, the 
terminals of low-threshold Aß cutaneous afferents, were un-
affected.  
Three phases of functional changes can be distinguished 
following the perineural application of capsaicin [21,100]: 
during the first phase, capsaicin elicits the activation of C 
and Aδ nerve fibres, producing cardiovascular reflexes, an-
tidromic neurogenic vasodilatation and extravasation. During 
the second phase, there is a blockade of the C- and to a lesser 
extent A-fibre impulse conduction. The last phase is charac-
terized by a total impairment of C-fibre functions distal to 
the site of capsaicin application. It includes complete chemi-
cal and thermal analgesia, and abolition of plasma protein or 
colloid extravasation [59,82] and neurogenic vasodilatation 
[101,102], i.e. neurogenic inflammation.  
The development of inflammation-induced thermal hy-
peralgesia, which is critically dependent on the activity of 
the TRPV1 channel, is also prevented by prior perineural 
treatment with capsaicin [84]. The development of mechani-
cal allodynia, which is transmitted by myelinated, capsaicin-
insensitive afferents, is also inhibited [84], probably due to 
the lack of nociceptive barrage preventing the central sensiti-
zation, a key mechanism of the tactile allodynia in the spinal 
dorsal horn. 
In other types of hyperalgesia models (post-incision and 
post-operative) evoked by a standard incision in the skin of 
the plantar surface, both perineural capsaicin [103,104] and 
resiniferatoxin [85] appeared to be highly effective in the 
prevention of thermal and mechanical hyperalgesia. Simi-
larly, cold hyperalgesia too could be inhibited by perineural 
capsaicin treatment [105]. 
Perineural capsaicin application further produces a selec-
tive blockade across the application site of the retrograde and 
anterograde axonal transport processes in chemosensitive 
afferent nerve fibres. Inhibition of the intraneural transport of 
a variety of peptides and proteins such as nerve growth fac-
tor (NGF), horseradish peroxidase, SP, CGRP, SOM and 
FRAP has been demonstrated [94]. However, axons proxi-
mal to the application site preserve their capacity to transport 
exogenous and possibly endogenous proteins such as wheat 
germ agglutinin-peroxidase conjugate (WGA-HRP) or CTB-
HRP [106,107].  
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The integrity and the function of unmyelinated sympa-
thetic C-fibre efferents and the myelinated low threshold Aß-
afferent and motor fibres remain intact; there are no distur-
bances in the mechano-sensitivity of the skin and deep tis-
sues, or the sympathetic vasoregulation and sweat secretion 
after perineural capsaicin. Trophic disturbances in the 
chemodenervated skin areas have never been observed in 
animals after perineural treatment with capsaicin [59,94]. 
An intriguing feature of perineural capsaicin treatment is 
its irreversible effect. The available data do not indicate any 
functional or morphological signs of re-innervation by che-
mosensitive nerve fibres following capsaicin-induced dener-
vation. This is somewhat surprising, since the nerve trunk, 
the Schwann cells and the capsaicin-insensitive afferent and 
efferent nerve fibres remain intact after this treatment. Inter-
estingly, collateral sprouting of intact chemosensitive nerves 
innervating skin areas adjacent to the chemodenervated skin 
and the consequent collateral reinnervation of the denervated 
skin has not been observed either after perineural application 
of capsaicin. This may be accounted for by the inhibition of 
collateral sprouting by the remaining intact nervous elements 
in the denervated skin or by the possible collateral damage of 
chemosensitive sensory ganglion neurones which innervate 
the adjacent intact skin areas [108].  
Neurotoxicity and Analgesia 
As outlined in the previous section of this review, cap-
saicin and related vanilloids can exert robust, but highly se-
lective neurodegenerative (neurotoxic) effects in a well-
defined population of somatic and visceral primary sensory 
neurones. Depending on the conditions of drug administra-
tion, vanilloids produce a severe overall disturbance in the 
metabolism of these cells, leading to the death and elimina-
tion of the affected neurones, or they exert a limited impair-
ment/destruction of specific (central or peripheral) domains 
of the pseudounipolar neurons (Fig. 1). In this latter case, 
loss of the central or the peripheral connections of the che-
mosensitive sensory neurones with the spinal dorsal horn or 
the peripheral receptive field, respectively, interrupts the 
transmission of nociceptive signals, causing selective chemo- 
and thermal analgesia. Moreover, after perineural (and in 
some cases topical) capsaicin application, but not after in-
trathecal capsaicin administration, the sensory efferent, local 
regulatory functions of the chemosensitive neurones are also 
abolished. Perineural application of capsaicin not only 
causes a complete absence of the neurogenic inflammatory 
reaction, but also reduces the intensity of inflammatory reac-
tions that basically have a non-neurogenic, e.g. immunologi-
cal origin [31,32,109].  
As far as we are aware, the neuronal effects in general, 
and the neurotoxic effects of vanilloids in particular, are me-
diated exclusively by the TRPV1 ion channel. Although 
there is evidence for the expression of TRPV1 in non-
neuronal cells, such as epidermal and urothelial cells, T-
lymphocytes, etc. [110,111] and in neurones in the central 
nervous system, this channel is most abundant in a specific 
population of primary sensory neurones. TRPV1 is a mem-
ber of the transient receptor potential family of ion channels 
characterized by a non-selective permeability for cations, 
including Ca2+ [14,15]. There are many chemical and physi-
cal factors which activate the TRPV1 channel, including 
noxious heat, protons and exogenous or endogenous vanil-
loid compounds [14,15,18]. There is also a complex interac-
tion between the thermal activation threshold and the trans-
membrane potential [112,113]. Numerous intracellular sig-
nalling pathways and mechanisms have been recognized 
which influence the gating mechanism by inducing an in-
crease or decrease in the activation threshold (sensitization) 
or render the receptor unresponsive (desensitization) 
[18,45,114-116]. Such action is brought about by covalent 
posttranslational modifications of the channel protein (phos-
phorylation) or non-covalent interactions with regulatory 
factors (e.g. PIP2). Trafficking and translocation of the pro-
tein between the cell membrane and intracellular compart-
ments have also been demonstrated as an additional level of 
the regulation of TRPV1 functions [115,117]. Apart from 
these mechanisms, which produce a rapid, short-term ad-
justment of the channel sensitivity, the long-term regulation 
of the TRPV1 gene expression, and finally the capsaicin sen-
sitivity of the sensory neurones are strongly influenced by 
neurotrophic factors derived from peripheral target organs 
and transported to the parent cell body via retrograde 
axoplasmic transport. NGF was initially regarded as an ef-
fective regulator of neuronal capsaicin sensitivity and 
TRPV1 expression [118-120]. However, later studies re-
vealed that other neurotrophins, such as glial-cell derived 
nerve growth factor (GDNF), also effectively increase the 
expression of TRPV1 [121-123]. It should be noted that no-
ciceptors, including the capsaicin-sensitive primary sensory 
neurones are a non-uniform mixed population which possess 
different neurochemical and functional traits, including the 
sensitivity and dependence on neurotrophic factors 
[124,125]. This heterogeneity of the capsaicin-sensitive pri-
mary sensory neurones (of adult animals) could undoubtedly 
significantly influence the susceptibility of these cells to-
wards capsaicin-induced neurotoxicity. Unfortunately, this 
issue has not yet been investigated in detail. It has been 
shown that there are primary sensory neurones which ex-
press the TRPV1 mRNA/protein at a significantly higher 
degree than other TRPV1-positive neurones [51,126]. On use 
of some neurochemical markers, this population appears to 
be unique, indicating a specific non-peptidergic (NGF recep-
tor TrkA-negative), and IB4-negative population in which 
some neurons express the GDNF receptor subunit RET. Al-
though it is plausible to suggest a mechanistic correlation 
between the level of expression of TRPV1 and the suscepti-
bility of neurones towards capsaicin toxicity [51], it should 
be noted that this specific group comprises only a small pro-
portion of the total neuronal population.  
Early in vivo observations by Jancsó and co-workers re-
vealed an increased accumulation of radioactive calcium in 
the sensory ganglia of capsaicin-treated (newborn) animals 
shortly (20 minutes) after the systemic administration of cap-
saicin. Ultrastructural histochemical analysis demonstrated 
Ca2+-containing deposits in the swollen mitochondria of 
small B-type sensory ganglion neurons, but not in the mito-
chondria of large A-type cells [29,30]. It has been concluded 
that this capsaicin-induced Ca2+ overload of the capsaicin-
sensitive neurones can contribute significantly to the neuro-
toxic action of this drug. The capsaicin-induced Ca2+ influx 
into the primary sensory neurones was later confirmed by 
many other groups, using histochemical, cellular electro-
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physiological and ratiometric imaging techniques [127-129]. 
It should be mentioned that capsaicin induced Ca2+ entry was 
also used as a functional trait during functional cloning ex-
periments, which finally led to the cloning of the capsaicin 
receptor protein VR1 [14].  
Numerous reports published recently were aimed at clari-
fication of the mechanisms of capsaicin and vanilloid-
induced cytotoxicity in different cell types, including cul-
tured primary sensory neurones, heterologous expression 
systems, immortalized cell lines or neoplastic cells, many of 
them of non-neuronal origin [130,131]. In these studies dif-
ferent methods were employed to detect neurotoxicity and 
cell degeneration with different morphological or biochemi-
cal end-points. A distinction should be made between 
TRPV1-dependent, i.e. selective, and TRPV1-independent, 
direct, non-selective toxic effects of capsaicin and related 
vanilloids. The conclusions drawn from the observations 
concerning the mechanism of capsaicin-induced neuro(cyto)-
toxicity should be evaluated with some caution, with regard 
to these differences.  
Early morphological observations indicated that high 
doses of capsaicin administered to rats produce significant 
changes in the integrity of the mitochondria in the affected 
sensory ganglion neurones. Although there are certain dis-
crepancies among the (early) publications in connection with 
the time course, the severity and, most importantly the final 
outcome of these changes [8,30,46,47,132,133], alterations 
in the mitochondrial functions seem to be critical in the me-
diation of the long-term effects of high concentration vanil-
loid/capsaicin administrations. It is not clear, however, to 
what extent the accumulation of Ca2+ in the mitochondrial 
matrix is the cause or a consequence of the impairment of the 
mitochondrial functions, including ATP synthesis and ion 
transport across the mitochondrial membrane [130]. There 
have been reports on the presence of functional TRPV1 
channels not only in the plasma membrane, but also in the 
intracellular membranes of the endoplasmatic reticulum, 
which are of importance in the intracellular Ca2+ handling. It 
has also been proposed that TRPV1 receptors localized in the 
plasma membrane serve as store-operated Ca2+-channels, 
while TRPV1 channels in the endoplasmatic reticulum act as 
Ca2+-release receptors. Furthermore, it has been demon-
strated that RTX, but not capsaicin can act directly on the 
IP3-dependent Ca2+-stores of the cells producing an intracel-
lular Ca2+-transient in the absence of extracellular Ca2+ 
[134]. However, there are apparently no reports on the local-
ization of TRPV1 in the mitochondrial membrane. Many 
researchers have suggested that an overload of intracellular 
Ca2+ depolarizes the mitochondrial transmembrane potential, 
which eventually leads to the opening of membrane potential 
transient (MPT) pores [135,136]. This non-selective perme-
abilization of the inner mitochondrial membrane, caused by 
the opening of MPT pores, leads to the loss of matrix com-
ponents, a mitochondrial dysfunction, and substantial swel-
ling of the mitochondria, with consequent outer membrane 
rupture and the release of apoptosis-inducing factors, includ-
ing cytochrome c from the mitochondria [137]. Indeed, an 
increase in the cytoplasmic cytochrome-c level, a prominent 
consequence of the membrane disruption and disintegration 
of the mitochondria, has been confirmed in different cell 
types following the application of TRPV1 agonists in toxic 
concentration [131,138]. There are however (at least) two 
alternative mechanisms which may finally lead to cell de-
generation or death: this can occur via either a necrotic or an 
apoptotic type of cell destruction. Necrosis can be regarded 
as death that ensues when a living cell is deprived of both 
glycolytic and oxidative ATP sources. Since neurones rely 
mainly on their mitochondrial oxidative ATP synthesis as the 
source of metabolic energy, it is plausible to conclude that 
acute destruction of the mitochondria will result in rapid 
necrosis of the neurones. The first reports, based on the ob-
served morphological signs of capsaicin-induced neurode-
generation and rapid elimination of the destroyed cells in 
vivo, postulated the necrotic type of cell death, as a dominat-
ing process. Recent in vitro experiments using capsaicin or 
resiniferatoxin to activate TRPV1 receptors confirm rapid, 
necrotic-type destruction of the affected neurones [139]. 
There are also observations on capsaicin-induced apoptotic 
cell death in both neurones and non-neuronal cell lines 
[130,140]. Biochemical and molecular biological analysis 
revealed the activation of different components of the (pro-
grammed) cell death cascade, including different types of 
caspases and enzymes of the ubiquitin pathway [141]. Con-
densation of the chromatin, nuclear shrinkage and DNA 
fragmentation have also been observed following capsaicin 
application in sensory neurones and in other, TRPV1-
expressing cells. Association of the TRPV1 receptor (com-
plex) with the Fas-associated Factor 1 (FAF1) protein was 
recently demonstrated (Kim, 2004). In certain cell types, 
FAF1 is linked to the Fas receptor, a membrane protein in-
volved in the signal transduction of many pro-apoptotic ef-
fects [142]. Although FAF1 alone is not able to activate 
downstream elements of the intracellular signalling of the 
death cascade, its role in TRPV1 activation-induced apopto-
sis can not be excluded.  
Impairment of the mitochondrial functions and uncou-
pling of the terminal oxidation also induces an increased 
production of reactive oxygen species (ROS), which play a 
crucial role in the neurotoxicity and neurodegeneration in a 
variety of neurodegenerative diseases. An increased produc-
tion of ROS has been demonstrated after capsaicin applica-
tion in TRPV1-transfected HEK cells; inhibition of ROS 
production, however, did not influence the development of 
apoptotic cell death [130]. It was therefore concluded that 
ROS do not play a significant role in capsaicin-induced 
apoptosis/cytotoxicity. 
It is highly possible that high concentrations of capsaicin 
in vivo produce neuronal degeneration and death via a mixed 
mechanism, causing an acute, necrotic-type degeneration in 
specific population(s) of capsaicin-sensitive neurones, but a 
delayed-type (apoptotic) cell death in other population(s) of 
sensory neurones. This assumption is supported by the find-
ing that, under in vitro conditions capsaicin produced both 
necrosis and apoptosis; the ratio of these events depended on 
the capsaicin concentration and on the TRPV1 expression of 
the transfected cells [130]. 
These considerations hold for the neurodegenerative ef-
fects of capsaicin and related vanilloids after systemic ad-
ministration of these drugs to adult and newborn animals in 
high, toxic doses. In the case of perineural, intrathecal or 
topical application of vanilloids, there are no signs of an 
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acute degeneration of sensory neurones in the related sensory 
ganglia. In these cases, in contrast with the systemic cap-
saicin application, the local concentration of capsaicin in the 
proximity of the nerve cell soma is presumably too low to 
induce any detectable morphological alterations in the pri-
mary sensory neurones. Following perineural capsaicin, a 
delayed type of neuronal degeneration, i.e. the loss of sen-
sory neurones and transganglionic degeneration or loss of the 
central nerve terminals, has been proposed. A significant 
reduction in the number of sensory neurones in the affected 
dorsal root ganglion neurones has been demonstrated follow-
ing transection or other non-selective mechanical injury of 
peripheral nerves [143-145]. Ultrastructural studies have 
disclosed a significant reduction in the number of glomeru-
lar-type afferent terminals in the superficial layers of the 
spinal dorsal horn, pointing to a possible transganglionic 
degeneration of primary sensory neurones [146,147]. Since 
the tendency to neuronal loss was reversible on the applica-
tion of high doses of NGF onto the proximal stump of the 
transected nerve, a critical role of the withdrawal of NGF 
(and probably other trophic factors) transported retrogradely 
to the perikarya under normal conditions was proposed in the 
mechanism of the axotomy-induced transganglionic degen-
eration [93]. It is plausible to assume that, after perineural 
(intracutaneous) capsaicin treatment, which causes a selec-
tive destruction of the peripheral axons of C-fibre afferent 
neurones, a similar, but restricted transganglionic degenera-
tion may occur in the spinal cord. Use of the capsaicin gap 
technique based on the systemic capsaicin treatment-induced 
argyrophilic degeneration of capsaicin-sensitive central ter-
minals revealed an almost complete depletion of these termi-
nals in the topographically related regions of the spinal dor-
sal horn corresponding to the treated peripheral nerves [83]. 
However later observations showed a concomitant decrease 
in the sensitivity to capsaicin-induced nerve terminal degen-
eration following transection of the peripheral nerve [98,99], 
and an axotomy- or perineural capsaicin treatment-induced 
downregulation of the TRPV1 receptor in both the spinal 
dorsal horn and the sensory ganglia [51]. The interpretation 
of the capsaicin gap therefore needs some refinement: during 
the given time frame (2 weeks p.o.), the loss of the cap-
saicin-induced argyrophilic degeneration may result mainly 
from the rapid loss of the capsaicin sensitivity rather than 
from a loss of central terminations. The transganglionic 
transport of a WGA-HRP conjugate, a specific marker of C-
fibre afferents, and CTb-HRP, a marker whose transport is 
enhanced in injured C-fibre afferents, was recently demon-
strated 2 weeks after axotomy or perineural capsaicin treat-
ment, indicating the presence and survival of a substantial 
population of C-fibre terminals, in the spinal dorsal horn at 
this time [106,107,148]. 
Overall, there is substantial evidence that capsaicin and 
related vanilloids cause obvious and selective neurodegen-
eration and neuronal death in a subset of primary sensory 
neurones in both neonate and adult animals. After systemic 
administration, all domains of the primary sensory neurones 
are affected, but the necrotic and probably to a lesser extent 
also the apoptotic neuron death is mainly due to a direct ac-
tion of capsaicin on the TRPV1 channels located in the 
plasma membrane and intracellular membrane structures. 
Both the capsaicin-induced Ca2+ overload and the impaired 
mitochondrial functions are of major importance in these 
processes. Delayed-type neurodegeneration, caused by a 
cessation of the supply of NGF and other neurotrophins due 
to the blockade of the axonal transport and/or the destruction 
of the peripheral axons, might complete the ongoing degen-
eration process. In sharp contrast, different types of localized 
capsaicin/vanilloid applications, including perineural cap-
saicin treatment, do not induce acute degeneration/death of 
the nociceptive sensory ganglion neurones, and the loss of C-
type sensory fibres, which becomes evident only weeks after 
the treatment might result in part from delayed degeneration 
and death of a limited number of sensory neurones.  
The Perspectives of TRPV1 Agonists in the Management 
of Pain 
Observations concerning the analgesic effects of cap-
saicin and other vanilloid agents in animal experiments indi-
cated that drugs with TRPV1 agonist potency may be con-
sidered for the management of pain in man. The possible use 
of capsaicin for the management of pain of peripheral origin 
was suggested some 30 years ago on the basis of animal 
studies showing marked increases in thermal and chemical 
nociceptive thresholds and a complete abolition of neuro-
genic inflammation following the local application of cap-
saicin onto peripheral nerves [149]. Further studies have 
confirmed and extended these observations and demon-
strated that perineural capsaicin treatment also effectively 
and selectively inhibits the function of chemosensitive (cap-
saicin-sensitive) nociceptor afferents in species other than 
the rat and mouse, including the rabbit, cat and monkey, re-
sulting in a defunctionalization of nociceptive somatic and 
visceral sensory afferent neurones [21,90,100]. Despite these 
encouraging findings in animal species, vanilloid compounds 
have been used only externally or topically to inhibit the 
function of chemosensitive afferent nerves in man 
[18,116,150]. However, such local treatment is impracticable 
for the management of severe chronic neuropathic or cancer 
pain. The findings in animal species as discussed in this re-
view strongly suggest that perineural and intrathecal applica-
tions of vanilloid agonists may prove useful approaches for 
pain relief under such conditions [151]. Capsaicin treatment 
of peripheral nerves which serve tissues from which pain 
may originate due to localized pathologies associated with 
pain may confer suitable antinociception by disrupting the 
conduction of noxious stimuli to the central nervous system. 
Studies showing an increase in nociceptive thresholds in 
human subjects after high-dose epidermal application or the 
intradermal injection of capsaicin support this assumption, 
for such treatments are very likely to reach the preterminal 
segments of the peripheral axons, producing effects resem-
bling the actions of perineural treatment with capsaicin 
[56,150]. Concerns as to possible unwanted or maladaptive 
changes induced by perineural vanilloid treatment may in-
clude the possible pain-producing effects of TRPV1 ago-
nists, traumatic/mechanical injury of the nerve and the con-
sequences of selective, but partial C-fibre deafferentation. 
The excitation of C-fibre axons [91,100,152] upon direct 
application of capsaicin onto a nerve is moderate, transient 
and short-lasting and may be well managed by the concomi-
tant use of local anaesthetics [86,153]. Deafferentation of the 
spinal cord brought about by the injuries to major nerve 
plexuses supplying the extremities may cause severe chronic 
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pain which is difficult to manage by pharmacological or neu-
rosurgical means. Hence, the possibility of the development 
of central pain by any procedure causing even partial deaf-
ferentation of the spinal dorsal horn should be considered 
[154]. The available experimental evidence indicates that 
perineural treatment results in an at least a partial loss of 
peripheral unmyelinated axons and possibly DRG cell loss 
and consequent deafferentation of the substantia gelatinosa 
of the spinal dorsal horn [21,82,89]. However, this deaffer-
entation is strictly confined to C-fibre afferents and there are 
no reports in the literature indicative of signs of deafferenta-
tion pain. Trophic functions are also known to be impaired 
by peripheral nerve injuries. Although perineural treatment 
results in the complete abolition of neurogenic sensory vaso-
dilatation and plasma extravasation, i.e. neurogenic inflam-
mation, which bears an important protective role under 
(patho)physiological conditions in the skin, cutaneous 
changes characteristic of trophic disturbances, e.g. skin ero-
sions, were not observed in rodents after perineural treatment 
with capsaicin [59,94].  
Intrathecal and intracisternal injections of capsaicin caused 
the selective degeneration of C-fibre capsaicin-sensitive pri-
mary afferent terminals in the upper spinal dorsal horn, as 
demonstrated in light and electron microscopic studies 
[72,74-76]. There is some evidence that dorsal root fibres are 
not affected directly by this treatment, and the peripheral 
“efferent” local regulatory functions of chemosensitive nerve 
endings remain intact following the administration of cap-
saicin into the subarachnoid space [76]. Although injection 
of capsaicin into the subarachnoid space induces a highly 
selective degeneration of primary afferent nerve terminals, 
this is apparently not associated with persistent pain or hy-
peralgesia [72,75,76], indicating that deafferentation pain 
does not develop. It appears, therefore, that the consequences 
of selective C-fibre deafferentation are substantially different 
from those of spinal deafferentation, which commences after 
lesions of both myelinated and unmyelinated dorsal root fi-
bres.  
A seminal trait of perineural and intrathecal/intracisternal 
capsaicin treatment is their largely irreversible nature 
[21,82,83]. The permanent loss of thermal and chemical pain 
sensations together with maintained sensitivity to noxious 
mechanical stimuli may not be critical for patients with se-
vere pain of neuropathic or malignant origin. However, the 
pros and cons need to be considered carefully. Intrathecal 
injections of capsaicin may prove to be an efficient way to 
reduce pain of inflammatory or cancer origin in the thoracic, 
abdominal and pelvic regions. Further studies are required to 
clarify the effects of intrathecal injections of capsaicin, in 
particular with regard to the regulation of visceral functions, 
such as bladder emptying [78]. 
Although capsacin is the archetypical sensory neurotoxin 
used first to evoke defunctionalization/degeneration of che-
mosensitive primary sensory neurones some other vanilloids 
(and TRPV1 agonists) exhibit similar or even higher potency 
to produce selective neurotoxicity in nociceptors. For exam-
ple resiniferatoxin is generally considered to have a 100-
1000 fold higher potency to activate and destroy capsaicin-
sensitive primary sensory neurones [155]. It has been 
claimed to have even more favourable pharmacokinetic and 
pharmacodynamic properties than those of capsaicin [156]. 
The arguments in support of resiniferatoxin seem to be well 
substantiated by findings such as its reduced pungency fol-
lowing topical (intravesical) administration [64,157], but 
others seem to be more circumstantial, such as the claim for 
its better toxicological properties. Such claims are otherwise 
not of great significance, if we consider only the local (topi-
cal, perineural or subarachnoid/epidural) therapeutic admini-
stration of vanilloids, which invovles a relatively small quan-
tity of drug, applied for a limited time with low frequency. A 
major advantage of capsaicin is its widespread use (even as a 
food constituent), and the large body of evidence that has 
accumulated on its biological and pharmacological actions in 
animal and human studies. The information available on the 
actions of capsaicin under clinical conditions is expected to 
increase further in the near future since new formulas con-
taining substantially higher concentrations of capsaicin than 
those of the earlier preparations have received permission for 
therapeutic use (topical or epicutaneous application) from the 
regulatory agencies in the USA and Europe [56,150,153,  
158,159]. The accessibility of high-concentration medical-
grade capsaicin preparations may also pave the way for the 
development and testing of more invasive (and targeted) 
therapeutic strategies, such as tissue infiltration, intra-
articular and intrathecal injections and perineural applica-
tions.  
Two new lines of development involving TRPV1 ago-
nist-based therapeutic approaches could also be of some in-
terest. Apart from the well-known “exogenous” TRPV1 ago-
nists, endogenous TRPV1 agonists may also exert selective 
defunctionalization and degeneration of the capsaicin-
sensitive nerves [151,160], possibly eliminating the concerns 
relating to the tolerability and toxicity of TRPV1 agonist 
drugs. Another concept might be the selective, but reversible 
blockade of the capsaicin-sensitive peripheral nerves by use 
of a combination of TRPV1 agonist (capsaicin) and water-
soluble local anaesthetic drug able to ingress through acti-
vated, but not inactive TRPV1 channels [161]. It has been 
demonstrated that the drug QX-314 can effectively and re-
versibly inhibit conduction in the C-fibres previously acti-
vated by low concentrations of capsaicin [161,162]. It is 
worthy of mention that capsaicin at the doses/concentrations 
used in these experiments may exert some analgesic actions 
by virtue of its selective neurotoxic/axonotoxic actions on C-
fibre nociceptors [55,71,92]. 
CONCLUDING REMARKS 
The inclusion of exogenous vanilloid agents of plant or 
synthetic origin or endogenous vanilloid compounds (endo-
vanilloids) with TRPV1 receptor agonist properties into the 
therapeutic arsenal of pain management offers a promising 
novel approach for the treatment of chronic pain of neuro-
pathic or malignant origin. Through careful choice of the 
appropriate route and dose for the administration of vanilloid 
agonists, selective targeting of the primary afferent fibres 
which convey nociceptive information from the diseased 
organs and tissues to the central nervous system seems pos-
sible. The large body of available experimental evidence 
indicates that vanilloid agonists exert their antinociceptive 
action through TRPV1 receptor-mediated selective neuro-
toxic/neurodegenerative effects directed against somatic and 
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visceral C-fibre nociceptive primary afferent fibres. Al-
though the effects of capsaicin applied onto peripheral 
nerves or injected into the subarachnoid space appear to be 
permanent and irreversible, further studies are needed to 
clarify the long-term effects and possible central and periph-
eral neuroplastic changes elicited by such treatment. Finally, 
it is expected that vanilloid agonists will broaden the palette 
of analgesic drugs which do not cause addiction and tachy-
phylaxis.  
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